Gilteritinib (ClinicalTrials.gov Identifier: NCT07140016), is a Phase 1b clinical trial evaluating an investigational oral therapy in adults with locally advanced or metastatic ALK-positive non-small cell lung cancer who have progressed after prior treatment with an ALK inhibitor. The trial is part of a multicenter research effort.

“OSF HealthCare continues to accelerate its role in early-phase cancer research, collaborating with global biotechnology partners to bring complex clinical studies to our region,” said Dr. Jun Zhang Vice President of Oncology Research at OSF HealthCare Cancer Institute. “By participating in clinical research, we are able to offer eligible patients the opportunity of early access to potentially life-saving treatments.”

The study includes evaluation of the investigational therapy, with all treatment approaches being studied for research purposes in accordance with the approved study protocol.

All clinical research conducted at OSF HealthCare undergoes rigorous review and ongoing oversight to help ensure patient safety and ethical conduct.

Patients interested in learning more about clinical research at OSF HealthCare are encouraged to speak with their care team, call (844) 673-4467 or Email: sfmc.clinicaltrials@osfhealthcare.org